ContraFect

About:

ContraFect is a biotechnology company researching the use of monoclonal antibodies to treat life-threatening infectious diseases.

Website: http://www.contrafect.com

Top Investors: Cormorant Asset Management, U.S. Department of Defense, Maxim Group, CARB-X, Oracle Investment Management Inc.

Description:

ContraFect is a biotechnology company pioneering the use of monoclonal antibodies to treat life-threatening infectious diseases. It addresses multi-drug resistant infections using therapeutic products from its lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses. Its novel lysins are enzymes that are produced in the life cycle stage of bacteriophage, a virus that infects and kills bacteria. The company was founded in 2008 and is headquartered in Yonkers, New York.